Esperion Therapeutics Inc... (ESPR)
1.60
-0.03 (-1.84%)
At close: Mar 27, 2025, 3:59 PM
1.60
0.04%
Pre-market: Mar 28, 2025, 07:33 AM EDT
Esperion Therapeutics Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY02 | FY01 | FY00 | FY99 |
| Revenue | 332.31M | 116.33M | 75.47M | 78.45M | 227.55M | 148.36M | 184.47M | n/a | n/a | n/a | n/a | 4.98B | n/a | n/a | n/a | n/a | 2K | n/a |
| Cost of Revenue | n/a | 43.27M | 26.97M | 14.22M | 2.39M | 175.61M | 265K | 258K | 252K | 236K | n/a | n/a | n/a | n/a | n/a | n/a | 786K | 683.22K |
| Gross Profit | 332.31M | 73.07M | 48.51M | 64.23M | 225.16M | -27.25M | 184.21M | -258K | -252K | -236K | n/a | 4.98B | n/a | n/a | n/a | n/a | -784K | -683.22K |
| Operating Income | 54.4M | -155.56M | -179.5M | -226.73M | -121.4M | -93.1M | -204.59M | -168.98M | -76.15M | -50.04M | -36.22M | -22.76M | -10.2M | -10.16M | -27.95M | -27.32M | -27.57M | -12.37M |
| Interest Income | n/a | n/a | 2.6M | 112K | 600K | 4M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Pretax Income | -51.74M | -209.25M | -233.66M | -269.11M | -143.55M | -97.17M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -31.37M | n/a |
| Net Income | -51.74M | -209.25M | -287.82M | -318.82M | -166.19M | -109.02M | -201.81M | -166.99M | -74.98M | -49.78M | -36.38M | -26.09M | -11.74M | -10.82M | -28.73M | -24.93M | -27.58M | -10.67M |
| Selling & General & Admin | 163.07M | 142.52M | 109.08M | 184.99M | 199.62M | 65.85M | 33.1M | 21.38M | 18.28M | 20.24M | 10.92M | 6.74M | 2.21M | 2.36M | 5.96M | 5.02M | 2.95M | 2.52M |
| Research & Development | 46.24M | 86.11M | 118.93M | 105.97M | 146.94M | 175.61M | 171.49M | 147.6M | 57.87M | 29.8M | 25.3M | 16.01M | 8M | 7.81M | 21.99M | 21.45M | 21.79M | 8.48M |
| Other Expenses | 68.6M | n/a | 2.65M | 3.98M | 515K | 4.06M | 2.77M | 2.19M | 1.55M | 776K | 119K | 194.01K | -83.65K | -75.81K | n/a | n/a | 5M | 3.2M |
| Operating Expenses | 277.91M | 228.63M | 228.01M | 290.96M | 346.55M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.2M | 10.16M | 29.24M | 29.33M | 26.79M | 11.69M |
| Interest Expense | 59.25M | 58.98M | 56.81M | 46.35M | 22.67M | 8.12M | 100K | 198K | 376K | 520K | 270K | 936.58K | 1.49M | 577.16K | n/a | n/a | n/a | n/a |
| Selling & Marketing Expenses | n/a | 15.6M | 11.3M | 13.7M | 19.3M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | 277.91M | 271.9M | 254.98M | 305.18M | 348.94M | 241.47M | 204.59M | 168.98M | 76.15M | 50.04M | 36.22M | 22.76M | 10.2M | 10.16M | 29.24M | 29.33M | 27.57M | 12.37M |
| Income Tax | n/a | n/a | 54.16M | 49.72M | 22.64M | 11.86M | 2.88M | 2.13M | 1.67M | 1.06M | 229K | 1.13M | 1.4M | 501.34K | 2.07M | 468K | 4.1M | -331.84K |
| Shares Outstanding (Basic) | 187.18M | 103.11M | 66.41M | 28.9M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.29M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| Shares Outstanding (Diluted) | 187.18M | 103.11M | 66.41M | 28.9M | 27.47M | 27.09M | 26.75M | 23.93M | 22.54M | 22.02M | 16.37M | 15.34M | 9.61M | 9.61M | 4.19M | 3.91M | 2.95M | 1.34M |
| EPS (Basic) | -0.28 | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.71 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EPS (Diluted) | -0.28 | -2.03 | -4.33 | -11.03 | -6.05 | -4.02 | -7.54 | -6.98 | -3.33 | -2.26 | -2.22 | -1.7 | -1.22 | -1.13 | -6.86 | -6.38 | -9.35 | -7.94 |
| EBITDA | 7.57M | -150.11M | -176.35M | -222.14M | -120.33M | -88.73M | -204.32M | -166.53M | -74.35M | -49.03M | -36.06M | -22.69M | -10.12M | -10.06M | -27.21M | -26.8M | -25.52M | -11.69M |
| Depreciation & Amortization | 63K | 164K | 500K | 612K | 547K | 319K | 265K | 258K | 252K | 236K | 160K | 70.55K | 139.43K | 178.47K | -1.29M | -2.01M | -2.05M | -683.22K |